Teprotumumab for chronic TED
3 February 2023
| Hetvi Bhatt
|
Oculoplastics, Orbit
|
Chronic, proptosis, teprotumumab, thyroid eye disease
This retrospective case series looks at the use of teprotumumab in nine patients with thyroid eye disease (TED) of clinical activity score ≤one and >nine months duration, in an American cohort. Current European guidelines have suggested the use of teprotumumab...
